Abstract: A brushless motor includes a rotor, the rotor including magnets and a core member. The magnets are arranged around a rotating shaft and sequentially arrayed with N poles or S poles facing each other in a circumferential direction. The core member includes: an annular portion around the rotating shaft; an outer peripheral core part which supports the magnets on an outer peripheral side of the annular portion; and bridges which extend radially between the annular portion and the outer peripheral core part. Each of the bridges is positioned between the magnets adjacent to each other in the circumferential direction. The bridges include one or more first bridges extending over a first range corresponding to a partial range of the core member along a direction of the rotating shaft.

Abstract: To provide a novel T-type calcium channel blocker. A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker.

Abstract: Provided is an overtube assembly including an overtube having an adjustable length. The overtube assembly has the overtube and a mouthpiece. The overtube has a plurality of recesses (e.g., grooves) on the outer circumference thereof. The mouthpiece has a locking portion (e.g., a protrusion or ridge) that is locked to the recesses. The mouthpiece can move between a locking position at which the locking portion engages with the recess and an unlocking position at which the locking portion does not engage with the recess.

Abstract: An information processing program is for improving operability of a player when aiming at one of a plurality of non-player objects. The information processing program causes a computer to function as: a camera control unit that controls an imaging range or an imaging direction of a virtual camera in a virtual space, a display control unit that causes a display unit to display an image taken by the virtual camera, an action control unit that controls an action of a player object in the virtual space according to an operation to an operating unit, and a setting unit that sets any one of the plurality of non-player objects other than the player object as a target object to aim at. The setting unit is capable of setting one of the plurality of non-player objects arranged outside the imaging range of the virtual camera as the target object.

Abstract: A detachable multi-ring traction device is inserted into a body through a forceps channel of an endoscope. When a lesion mucosa in the body is resected through an operation performed outside the body, the detachable multi-ring traction device is configured to be fixed by a clip to the lesion mucosa and a normal mucosa in order to pull the lesion mucosa, the normal mucosa opposing the lesion mucosa. The detachable multi-ring traction device includes toroidal rings each including a core curve and a meridional disk, the rings being coupled to each other such that outer edges of two adjacent ones of the rings are in contact with each other and the rings are connected to each other in a diametrical direction of the core curves.

Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a 5-membered heteroaryl group or a fused ring of a 5-membered or 6-membered heterocyclic ring with a benzene ring or a pyridine ring, each of which may have a substituent; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent, or the like; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2.

Abstract: A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.

Abstract: An information processing program is for improving operability of a player when aiming at one of a plurality of non-player objects. The information processing program causes a computer to function as: a camera control unit that controls an imaging range or an imaging direction of a virtual camera in a virtual space, a display control unit that causes a display unit to display an image taken by the virtual camera, an action control unit that controls an action of a player object in the virtual space according to an operation to an operating unit, and a setting unit that sets any one of the plurality of non-player objects other than the player object as a target object to aim at. The setting unit is capable of setting one of the plurality of non-player objects arranged outside the imaging range of the virtual camera as the target object.

Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydr

Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydr

Abstract: A motor with a speed reducer includes a motor (4) received in a motor housing (2), a speed reducer (5) received in the motor housing (2) and that is driven by receiving power from a motor shaft of the motor (4) and that reduces rotation of a rotor boss (43) and outputs the reduced rotation, and a drive shaft (7) received in the motor housing (2), connected to an output shaft (58) of the speed reducer (5) via a transmission belt (6) and that drives a driven body, wherein the rotor boss (43) and the output shaft (58) are disposed coaxially, and the output shaft (58) and the drive shaft (7) are disposed parallel in a radial direction.

Abstract: A relay device may include a plurality of communication circuits and a state control portion. The relay device may relay the data among a plurality of buses, each of which connecting one or more nodes. The plurality of communication circuits may perform transmission and reception of the data, and transition among a plurality of states including a transmission enabled state and a transmission disabled state. The plurality of communication circuits may be connected to the plurality of buses in one to one manner. The state control portion may cause a specific communication circuit to transition from the transmission enabled state to the transmission disabled state when a relay transition time has elapsed from an occurrence of predetermined event. The specific communication circuit may represent at least one of the plurality of communication circuits to which at least one of the plurality of buses connecting the specific node is connected.

Abstract: A brushless motor (18) which supplies currents to coils (U1, U2, V1, V2, W1, and W2) and rotates a rotor (27), the brushless motor comprising a control apparatus (37) which switches and selectively executes: first energization control to start energization to the coils (U1, U2, V1, V2, W1, and W2) at first timing, and to continue the energization for a first period to control the rotation number of the rotor (27); and second energization control to start energization to the coils (U1, U2, V1, V2, W1, and W2) at second timing advanced by an electric angle with respect to the first timing, and to continue the energization for a second period longer than the first period to control the rotation number of the rotor (27).

Abstract: In a 4-pole, 6-slot, 18-segment electric motor, one forward winding coil (91) and two reverse winding coils (92, 93) are wound on each tooth (12). When the forward winding coils are formed of coils corresponding to a U phase, a V phase, and a W phase and the reverse winding coils are formed of coils corresponding to a “?U” phase, a “?V” phase, and a “?W” phase, the coils, which correspond to a U phase, a “?W” phase, a “?W” phase, a V phase, a “?U” phase, a “?U” phase, a W phase, a “?V” phase, and a “?V” phase, are electrically connected in this order between the adjacent segments.

Abstract: In a brush holder accommodating part 26d of a gear housing 26, paired flat surface parts 26c and paired curved parts 26b are alternately disposed so as to be formed into an elliptical shape, one of the paired flat surface parts is formed with first heat sinks 26i, and two brushes 20 and 20 mounted on a brush holder unit 19 accommodated in the brush holder accommodating part 26d are disposed near the first heat sinks 26i.

Abstract: A relay device may include a plurality of communication circuits and a state control portion. The relay device may relay the data among a plurality of buses, each of which connecting one or more nodes. The plurality of communication circuits may perform transmission and reception of the data, and transition among a plurality of states including a transmission enabled state and a transmission disabled state. The plurality of communication circuits may be connected to the plurality of buses in one to one manner. The state control portion may cause a specific communication circuit to transition from the transmission enabled state to the transmission disabled state when a relay transition time has elapsed from an occurrence of predetermined event. The specific communication circuit may represent at least one of the plurality of communication circuits to which at least one of the plurality of buses connecting the specific node is connected.

Abstract: A compound represented by the following formula (I) or the formula (II) disclosed in the specification is a GPR119 agonist, and is used as an agent for treating diabetes: wherein one of T1, T2, T3, and T4 is N, and each of the other three independently is CR4 or, in the alternative, each of the four independently is CR4; each of R2 and R3 is hydrogen or a C1-8 alkyl group; the double line consisting of a solid line and a broken line means a single or double bond; A is (CH2)m, a bond, or the like; B is (C(R5)H)n, a bond, or the like; one of U and V is N, and the other is CR7; W is C or CR8; each of X and Y is a C1-3 alkylene group, which optionally has a halogen atom, hydroxyl etc.; Z is C(O)OR9, C(O)R10, or the like.

Abstract: A wiper motor has: a magnet disposed on the yoke and formed with at least four poles; an armature disposed on an inner side of the magnet; a speed reduction mechanism unit having an output shaft for transmitting the rotation of the armature shaft; a gear housing connected to the yoke; a gear housing cover covering an opening of the gear housing; a magnet attached to the output shaft of the speed reduction mechanism unit; an absolute position detecting sensor disposed so as to face the magnet; and a control board having the absolute position detecting sensor attached thereto, the control board being disposed between the gear housing and the gear housing cover, and configured to control the rotation of the armature shaft.

Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each repres

Abstract: Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia.